Newsroom
Featured News
- Investors10 November 2023
Lotus Hosts Third Quarter 2023 Results Investor Conference
- Investors10 November 2023
Lotus Reported Unaudited October Consolidated Revenues of NT$912 million, Marking a Nearly 10% YoY Growth Accumulated Unaudited Consolidated Revenue for the Frist Ten Months Recorded NT$14.45 billion, with 17.58% YoY Growth
- Investors09 November 2023
Lotus Achieves Historic Q3 2023 Results with YTD EPS Soaring to a Record NTD 14.19 Marking a 29% Year-on-Year Growth
- Investors11 October 2023
Lotus Pharmaceutical Co., Ltd. Reports Solid Financial Results for September 2023 and Year-to-Date Growth
- People27 September 2023
Lotus Pharmaceutical Collaborates with Ministry of Labor's Workforce Development Agency to Boost Talent Training in Taiwan's Pharmaceutical Sector
- Business18 September 2023
Lotus and Adalvo launch Gabapentin ER in South Korea
- Investors11 September 2023
Lotus Reported Unaudited August Consolidated Revenues of NT$1,185 million, 19% YoY Growth
- Investors11 August 2023
Lotus Continued Stelar Growth in 2Q 2023 EPS Recorded NTD 4.85 with 285% Growth Year on Year
- Investors10 August 2023
Lotus July Revenues Soar to NT$2.288 Billion, Marking a 119% YoY Surge
